Clinical Trials on CD4 Cell Counts in Australia

Total 2486 results

Dren Bio
Novotech

Recruiting

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Aggressive NK Cell Leukemia | Hepatosplenic T-cell Lymphoma | Enteropathy-Associated T-Cell Lymphoma | Subcutaneous Panniculitis-Like T-Cell Lymphoma | Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma | LGLL - Large Granular Lymphocytic Leukemia | Primary Cutaneous T-Cell Lymphoma - Category and other conditions

United States, Australia, France, Spain
University of Colorado, Denver
National Institute of Neurological Disorders and Stroke (NINDS); National Institutes... and other collaborators

Recruiting

International CDKL5 Clinical Research Network (ICCRN)

CDKL5 | CDKL5 Deficiency Disorder | CDD

United States, Australia
Glycomine, Inc.

Recruiting

24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG

Pmm2-CDG

Spain, Australia, United States
Novartis Pharmaceuticals

Terminated

To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC)

Sporadic Superficial and Nodular Skin Basal Cell Carcinomas

Austria, Australia
Trans Tasman Radiation Oncology Group

Active, not recruiting

Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPVOropharynx)

HPV Positive Oropharyngeal Squamous Cell Carcinoma

Australia, New Zealand
Amgen

Terminated

Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer

NSCLC | Non-small Cell Lung Cancer

United States, Austria, Australia
Genor Biopharma Co., Ltd.

Recruiting

A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.

CLL | B Cell NHL

Australia
Bristol-Myers Squibb

Active, not recruiting

An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia

Melanoma

Australia
Australasian Leukaemia and Lymphoma Group

Recruiting

A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. (GOlDiLOX)

Mantle Cell Lymphoma | Mantle Cell Lymphoma Refractory

Australia
Iksuda Therapeutics Ltd.

Recruiting

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

Follicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non-Hodgkin Lymphoma

Australia, Canada, United States
Galderma R&D

Completed

Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma

Basal Cell Carcinoma

Australia
Novartis Pharmaceuticals

Terminated

Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

Cutaneous Squamous Cell Carcinoma in Situ (CSCCis)

Belgium, Australia, United States
Queensland Centre of Excellence for Head and Neck...
Princess Alexandra Hospital, Brisbane, Australia; Queensland Health Forensic...

Suspended

Identification of Breath Biomarkers in Head and Neck Squamous Cell Carcinoma

Oropharyngeal Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma

Australia
Novartis Pharmaceuticals

Terminated

Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma (CATChEz)

Carcinoma, Renal Cell

Australia, Korea, Republic of
TG Therapeutics, Inc.

Completed

Study of TG-1801 in Subjects With B-Cell Lymphoma

B-Cell Lymphoma

Australia
Trans Tasman Radiation Oncology Group

Unknown

Hypofractionated Radiotherapy (Stereotactic) Versus Conventional Radiotherapy for Inoperable Early Stage I Non-small Cell Lung Cancer (NSCLC) (CHISEL)

Non Small Cell Lung Cancer

Australia, New Zealand
Queensland Centre of Excellence for Head and Neck...
The University of Queensland; Princess Alexandra Hospital, Brisbane, Australia and other collaborators

Unknown

The Princess Alexandra Hospital and the QIMR Berghofer Medical Research Institute Head and Neck Cancer Study

Head and Neck Squamous Cell Carcinoma | Human Papillomavirus

Australia
Telix International Pty Ltd

Recruiting

131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) (IPAX-2)

Glioblastoma | Glioblastoma Multiforme | Neoplastic Disease

Australia, Austria, Netherlands, New Zealand
Peter MacCallum Cancer Centre, Australia
Sanofi; Regeneron Pharmaceuticals; Monash University; University of Adelaide; University...

Recruiting

Deep sequencIng in Cutaneous Squamous CEll caRciNomas (DISCERN)

Neoplasms | Cutaneous Squamous Cell Carcinoma of the Head and Neck | Non-melanoma Skin Cancer | Cutaneous Squamous Cell Carcinoma

Australia
Dizal Pharmaceuticals

Not yet recruiting

DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

Australia
German Breast Group
Pfizer; AGO Study Group; Breast International Group; NSABP Foundation Inc

Completed

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery (PENELOPE-B)

Breast Cancer | Hormonreceptor Positive | Her2-normal | Postneoadjuvant Treatment With CDK 4/6 Inhibitor | CPS-EG Score

United States, Australia, Austria, Canada, France, Germany, Ireland, Japan, Korea, Republic of, Spain, United Kingdom
Peter MacCallum Cancer Centre, Australia

Terminated

Phase 0 of 18F FPM Using PET/CT in Patients With a Variety of Malignancies

Squamous Cell Carcinoma

Australia
Sung Hyun Pyun

Unknown

Diagnosing Melanoma, Squamous Cell Carcinoma and Basal Cell Carcinoma Using the Spectra-Scope

Skin Cancer

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma Refractory

Australia
Peter MacCallum Cancer Centre, Australia
Hoffmann-La Roche

Active, not recruiting

A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) (COALITION)

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma

Australia
Radiopharm Theranostics, Ltd

Recruiting

177Lu-anti-PD-L1 sdAb in Metastatic Non-small Cell Lung Cancer

Non Small Cell Lung Cancer | PDL1 Gene Mutation

Australia
BeiGene

Completed

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

B-cell Malignancies

Australia
Melanoma and Skin Cancer Trials Limited

Recruiting

Targeted Therapy and Avelumab in Merkel Cell Carcinoma (GoTHAM)

Metastatic Merkel Cell Carcinoma

Australia
Peplin

Completed

PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities

Superficial Basal Cell Carcinoma

Australia
South Metropolitan Health Service
Telix Pharmaceuticals (Innovations) Pty Limited

Completed

Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients (ZiPUP)

Urothelial Carcinoma

Australia
Peter MacCallum Cancer Centre, Australia
GlaxoSmithKline; Merck Sharp & Dohme LLC

Terminated

A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) (VEIL)

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma

Australia
Peter MacCallum Cancer Centre, Australia
Melbourne Health; Westmead Hospital; Victorian Infectious Diseases Reference...

Completed

PET/CT and Bacterial/Fungal PCR in High Risk Febrile Neutropenia (PIPPIN)

Acute Myeloid Leukemia | Febrile Neutropenia | Acute Lymphoblastic Leukemia | Haematopoietic Stem Cell Transplant, Autologous | Haematopoietic Stem Cell Transplant, Allogeneic

Australia
Galderma R&D

Completed

PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call Carcinoma

Basal Cell Carcinoma

Australia
Peplin

Completed

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma

Basal Cell Carcinoma

Australia
Peter MacCallum Cancer Centre, Australia
Novartis

Active, not recruiting

Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma (TARMAC)

Mantle Cell Lymphoma Recurrent

Australia
Peter MacCallum Cancer Centre, Australia

Completed

Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma (EpiBrentlen)

Hodgkin Lymphoma | Lymphoma, T-Cell, Cutaneous | Lymphoma, T-Cell, Peripheral

Australia
Merck Sharp & Dohme LLC
Moderna TX

Recruiting

A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)

Carcinoma, Squamous Cell | Skin Neoplasms

Australia, Israel
Telix International Pty Ltd

Completed

131I-IPA and Concurrent XRT in Recurrent GBM (IPAX-1)

Glioblastoma Multiforme

Austria, Australia, Netherlands
Royal North Shore Hospital

Not yet recruiting

De-escalation of Radiation Dose in HPV-associated OPC Utilising FMISO PET (DE-RADIATE) (DE-RADIATE)

HPV Positive Oropharyngeal Squamous Cell Carcinoma

Australia
Peplin

Completed

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma

Basal Cell Carcinoma

Australia
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)

Malignant Melanoma Stage III

Austria, Netherlands, Australia, Sweden
Benitec BioPharma Ltd

Completed

A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

Australia, Russian Federation
Melanoma Institute Australia

Active, not recruiting

Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma (Neo Combi)

Melanoma

Australia
Graceway Pharmaceuticals, LLC

Completed

Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream

Superficial Basal Cell Carcinoma

Australia, New Zealand
Lipotek Pty Ltd
Royal Adelaide Hospital; Trident Clinical Research Pty Ltd

Completed

Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma

Melanoma

Australia
Ipsen

Active, not recruiting

A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072

Neuroendocrine Tumors

Austria, Denmark, Switzerland, Australia, United Kingdom, France
Hummingbird Bioscience
Merck KGaA, Darmstadt, Germany

Recruiting

Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Australia, Singapore
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

Recruiting

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | MALT Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Indolent Lymphoma | Refractory B-Cell Lymphoma

United States, Australia, China
Ludwig Institute for Cancer Research
Pfizer; Heidelberg Pharma AG

Terminated

Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma

Renal Cell Carcinoma (RCC)

Australia
Peter MacCallum Cancer Centre, Australia

Completed

High Intensity Functional Image Guided Vmat Lung Evasion (HI-FIVE)

Non Small Cell Lung Cancer Stage III

Australia

Clinical Trials on CD4 Cell Counts in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations